<DOC>
	<DOCNO>NCT02988960</DOCNO>
	<brief_summary>This dose-escalation study design evaluate safety , pharmacokinetics , pharmacodynamics ABBV-927 , determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RPTD ) ABBV-927 administer monotherapy combination therapy nivolumab participant advance solid tumor .</brief_summary>
	<brief_title>A Study ABBV-927 , Immunotherapy , Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Participants adequate bone marrow , kidney liver function . Participants monotherapy arm must advance solid tumor progress standard therapy know provide clinical benefit participant intolerant therapy . Participants combination therapy arm must advance solid tumor indicate standard care nivolumab . Active prior document autoimmune disease last 2 year . Current prior use immunosuppressive medication within 14 day prior first dose ( certain exception ) . History primary immunodeficiency , bone marrow transplantation , chronic lymphocytic leukemia , solid organ transplantation , previous clinical diagnosis tuberculosis . Prior grade great equal 3 immunemediated neurotoxicity pneumonitis receive immunotherapy . Known uncontrolled malignancy central nervous system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Squamous cell carcinoma head neck ( SCCHN )</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Cutaneous melanoma</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Cancer</keyword>
</DOC>